Diabetes currently affects more than 62 million Indians, which is more than 7.1% of the adult population. The average age on onset is 42.5 years. Nearly 1 million Indians die due to diabetes every year.We have presence in Diabetes Therapy Area (TA) through our Diabetology & Metabolics Division. This reinforces our commitment to help patients manage their diabetes better and improve their Quality of Life (QoL). We have brands like Olymprix M, Olymprix, Glucoryl-M, Glucoryl-MV, Voglikem, Euclide – M, Formin - PG in diabetes therapy. Alkem’s commitment to fight Diabetes has led it to partner with the No.1 Company of South Korea and launch Evogliptin( VALERA) in India .We have exclusivity to market Evogliptin( VALERA) in India . This launch has further strengthened our position in the Gliptin category, which includes Olymprix and Olymprix - M.
Our aim is to be a key player in the Diabetes Therapy by providing affordable solutions to millions of diabetics across India.
Some of our key brands are: